Plixorafenib + Cobicistat 150 MG [Tybost]
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
BRAF V600E Mutation
Conditions
BRAF V600E Mutation
Trial Timeline
Apr 7, 2025 → Jun 30, 2027
NCT ID
NCT06610682About Plixorafenib + Cobicistat 150 MG [Tybost]
Plixorafenib + Cobicistat 150 MG [Tybost] is a phase 1 stage product being developed by Brain Biotech for BRAF V600E Mutation. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06610682. Target conditions include BRAF V600E Mutation.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06610682 | Phase 1 | Recruiting |
Competing Products
13 competing products in BRAF V600E Mutation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PLX3397 + vemurafenib | Daiichi Sankyo | Phase 1 | 33 |
| TMZ + E7016 | Eisai | Phase 2 | 52 |
| Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-Fluorouracil | Ono Pharmaceutical | Phase 3 | 77 |
| encorafenib + Binimetinib + Cetuximab | Ono Pharmaceutical | Phase 2 | 52 |
| Encorafenib + Cetuximab + FOLFIRI | Merck | Phase 2 | 52 |
| Tafinlar/Mekinist | Novartis | Pre-clinical | 23 |
| BKM120 Combined with Vemurafenib (PLX4032) | Novartis | Phase 1/2 | 41 |
| Dabrafenib + LTT462 + Trametinib + LXH254 + TNO155 + Spartalizumab + Tislelizumab | Novartis | Phase 1 | 33 |
| Cobimetinib + Atezolizumab + Pembrolizumab | Roche | Phase 3 | 77 |
| LGX818 + MEK162 + LEE011 | Pfizer | Phase 1/2 | 40 |
| MEK162 | Pfizer | Phase 2 | 51 |
| Encorafenib + Binimetinib + cemiplimab+fianlimab | Regeneron Pharmaceuticals | Phase 2 | 51 |
| Dabrafenib + Trametinib + Hydroxychloroquine | Brain Biotech | Phase 1/2 | 33 |